Decoding Nature, Advancing Health
Our rigorous three-pillar model functions as an integrated value chain: identifying high-potential "hits" via predictive modeling with our AI-first discovery platform, then transitioning them seamlessly for proactive wellness as Nutraceuticals or for clinical development through Therapeutics.
Discovery Platform
Learn More
AI-First Compound Discovery
Unlocking novel bioactive compounds by merging AI with natural chemistry. We screened 700,000 compounds for a client in just five months—7x the capacity of conventional databases.
The Edge: A 40% hit rate for AI-prioritized candidates, performing up to 40x higher than virtual screening.
Nutraceuticals
Learn MoreNutraceuticals
We translate deep discovery into proactive health solutions. Our platform identifies not just the active compound, but the science-validated dosage required for real-world efficacy.
The Edge: Identified over 3,500 potential mental health candidates for a client from a library of 700,000 compounds.
Therapeutics
Learn MoreTherapeutics
We advance high-potential compounds into first-in-class drug candidates with unprecedented efficiency, targeting unmet needs across complex disease states.
The Edge: Progressing from raw plant source to preclinical candidate in under three years—nearly 50% faster than the industry average.
AI-First Compound Discovery
Unlocking novel bioactive compounds by merging AI with natural chemistry. We screened 700,000 compounds for a client in just five months—7x the capacity of conventional databases.
The Edge: A 40% hit rate for AI-prioritized candidates, performing up to 40x higher than virtual screening.
Nutraceuticals
We translate deep discovery into proactive health solutions. Our platform identifies not just the active compound, but the science-validated dosage required for real-world efficacy.
The Edge: Identified over 3,500 potential mental health candidates for a client from a library of 700,000 compounds. Since then, our natural compound library has grown to over 1.5 million compounds.
Therapeutics
We advance high-potential compounds into first-in-class drug candidates with unprecedented efficiency, targeting unmet needs across complex disease states.
The Edge: Progressing from raw plant source to preclinical candidate in under three years—nearly 50% faster than the industry average.
%201.avif)
The AI-First Disrupter: Precision at Scale
Powered by one of the world’s largest natural compound libraries and our proprietary AI models, we have moved beyond traditional virtual screening.
27.03%
in bioactivity prediction vs leading industry models (as published in the Journal of Biomedical and Health Informatics).
700K
screened for a client in just 5 months - 7x conventional capacity. Since then, our natural compound library has grown to over 1.5 million compounds.
40%
for AI-prioritized candidates - Up to 40x higher than standard screening
.jpg)
